Login to Your Account

Potential Sickle Cell Disease Treatments on the Horizon

By Peter Winter

Monday, September 17, 2012

Brian Culley, CEO of Adventrx Pharmaceuticals Inc., is a busy man these days. Not only is his company readying itself for an important Phase III trial, but he also is in the midst of organizing the first Sickle Cell Disease Therapeutics Conference that will be held this week, Sept. 19, in New York City.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription